The Study of DNA Methyltransferase-3B Promoter Variant Genotype among Iranian Sporadic Breast Cancer Patients

Authors

  • Ebrahim Eftekhar Deparment of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran;and Student Research Committee, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; and Department of Biochemistry, School of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
  • Fakhraddin Nahgibalhossaini Deparment of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
  • Mozhgan Rasti Deparment of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
  • Yasaman Sadeghi Student Research Committee, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract:

Background: DNA methyltransferase-3B (DNMT3B) is an important enzyme responsible for maintaining the DNA methylation pattern in eukaryotic cells. In this study we have investigated the correlation between the 46359C→T polymorphism in the DNMT3B gene and the risk of breast cancer incidence among sporadic breast cancer patients in Fars Province, Southern Iran.Methods: In this case-control study, 100 breast cancer patients and 138 healthy control subjects were genotyped for the DNMT3B gene by the polymerase chain reaction-restriction fragment length polymorphism method.Results: The genotype frequency in the case (CC 27%, CT 47%, TT 26%) group significantly (P=0.008) differed from the control (CC 19.56%, CT 67.3%, TT 13%) group. We observed a decreased association between the CT genotype and lymph node involvement in breast cancer patients. Our results have shown that in comparison to the homozygous CC genotype carriers the DNMT3B-CT genotype has a significantly lower risk for breast cancer (OR=0.515, 95% CI=0.267-0.994, P=0.048).Conclusion: Our case-control study showed that the CT genotype was significantly associated with decreased breast cancer risk. Consistent with these results, a significant decrease of CT genotype among lymph node positive breast cancer patients was observed. However, a larger study population with more clinical data is needed to confirm these results.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

the study of dna methyltransferase-3b promoter variant genotype among iranian sporadic breast cancer patients

background: dna methyltransferase-3b (dnmt3b) is an important enzyme responsible for maintaining the dna methylation pattern in eukaryotic cells. in this study we have investigated the correlation between the 46359c→t polymorphism in the dnmt3b gene and the risk of breast cancer incidence among sporadic breast cancer patients in fars province, southern iran. methods: in this case-control study,...

full text

the study of aaag repeat polymorphism in promoter of errg gene and its association with the risk of breast cancer in isfahan region

چکیده: سرطان پستان دومین عامل مرگ مرتبط با سرطان در خانم ها است. از آنجا که سرطان پستان یک تومور وابسته به هورمون است، می تواند توسط وضعیت هورمون های استروئیدی شامل استروژن و پروژسترون تنظیم شود. استروژن نقش مهمی در توسعه و پیشرفت سرطان پستان ایفا می کند و تاثیر خود را روی بیان ژن های هدف از طریق گیرنده های استروژن اعمال می کند. اما گروه دیگری از گیرنده های هسته ای به نام گیرنده های مرتبط به ا...

15 صفحه اول

DNA-methyltransferase 3B 39179 G > T polymorphism and risk of sporadic colorectal cancer in a subset of Iranian population

BACKGROUND Epigenetic event is a biological regulation that influences the expression of various genes involved in cancer. DNA methylation is established by DNA methyltransferases, particularly DNAmethyltransferase 3B (DNMT3B). It seems to play an oncogenic role in the creation of abnormal methylation during tumorigenesis. The polymorphisms of the DNMT3B gene may influence DNMT3B activity in DN...

full text

Methylation Analysis of 5’UTR Promoter Region of DBC2 as a Biomarker in the Peripheral Bloods of Some Iranian Women with Sporadic Breast Cancer

Background and Objective: The DBC2 (deleted in breast cancer 2) or RhoBTB2 (Located on 8p21) is a tumor suppressor gene associated with tumorigenesis. Mutational studies of DBC2 at its promoter region in breast cancer revealed an important role for epigenetic changes contributing to its low expression. Epigenetic changes through hypermethylation of the promoter can cause the inactivation of DBC...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 39  issue 3

pages  268- 274

publication date 2014-05-01

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023